NCT03981380

11C-PIB PET Study in MESA at Columbia University

11C-PIB PET Study in the Multi Ethnic Study of Atherosclerosis at Columbia University

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 59 (actual)
• Sponsor: José A. Luchsinger · Academic / Other
• Sex: All
• Age: 60 Years
• Healthy volunteers: Not accepted

Summary

The investigators will conduct a study of brain positron emission tomography (PET) using 11C-PIB for the imaging of brain amyloid in 250 participants in the Multiethnic study of atherosclerosis (MESA) at Columbia University Irving Medical Center in New York City. Participants will be imaged only once with Pittsburgh Compound B (PIB) PET.

Detailed description

This is a single center PET study of 11C-PIB. Eligible participants are current participants in the MESA study in New York City, without contraindications to MRI or PET procedures. Those eligible will have one brain PET scan with 11C-PIB within 12 months of a brain MRI. Vital signs will be checked prior to injection of 11C-PIB, 10 minutes after the injection, and again at the completion of the PET scan. The primary outcome measure for amyloid will be whole brain 11C-PIB SUVR. The relation between exposure groups and amyloid in the brain will be analyzed using linear regression.

Conditions

• Cognitive Impairment
• Vascular Diseases
• Alzheimer Disease
• Atherosclerosis

Interventions

Type	Name	Description
DRUG	11C-PIB	Participants will be injected with an intravenous bolus of up to 5-15mCi (370 MBq) (+/-10%) of \[11C\]PiB (over 5-10 seconds).

Timeline

• Start date: 2020-08-01
• Primary completion: 2024-02-05
• Completion: 2024-02-05
• First posted: 2019-06-10
• Last updated: 2025-02-18

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study